Brief: Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date For Acer-001
07/06/2022 13:42
June 7 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ISSUES STATEMENT REGARDING PDUFA TARGET
ACTION
DATE FOR ACER-001
* ACER THERAPEUTICS - NOT YET RECEIVED A DECISION FROM FDA
ON ITS
NDA FOR ACER-001 FOR TREATMENT OF UREA CYCLE DISORDERS (UCDS)
* ACER THERAPEUTICS INC - WILL ISSUE A PRESS RELEASE ONCE
FDA HAS
PROVIDED ITS WRITTEN DECISION TO COMPANY
Source text for Eikon: ID:nGNX4r5g1n
Further company coverage: ACER.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31